Examining the association between monthly migraine frequency and quality of life: Post hoc analyses of outcomes data from the topiramate migraine trials

被引：0
|
作者：
Diamond, M
Dahlof, C
Mao, L
Rupnow, M
Papadopoulos, G
Greenberg, S
机构：
[1] Diamond Headache Clin Ltd, Chicago, IL USA
[2] Inst Clin Neurosci, Gothenburg, Sweden
[3] Ortho McNeil Pharmaceut, Raritan, NJ USA
[4] Janssen Med Affairs LLC, Titusville, NJ USA
来源：
HEADACHE | 2005年 / 45卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：778 / 778
页数：1
相关论文
共 50 条
  • [31] Reduction in acute migraine-specific and non-specific medication use in patients treated with erenumab: post-hoc analyses of episodic and chronic migraine clinical trials
    Tepper, Stewart J.
    Ashina, Messoud
    Reuter, Uwe
    Hallstroem, Yngve
    Broessner, Gregor
    Bonner, Jo H.
    Picard, Hernan
    Cheng, Sunfa
    Chou, Denise E.
    Zhang, Feng
    Klatt, Jan
    Mikol, Daniel D.
    JOURNAL OF HEADACHE AND PAIN, 2021, 22 (01):
  • [32] Matching-adjusted indirect comparisons of oral rimegepant versus placebo, erenumab, and galcanezumab examining monthly migraine days and health-related quality of life in the treatment of migraine
    Popoff, Evan
    Johnston, Karissa
    Croop, Robert
    Thiry, Alexandra
    Harris, Linda
    Powell, Lauren
    Coric, Vladimir
    L'Italien, Gilbert
    Moren, James
    HEADACHE, 2021, 61 (06): : 906 - 915
  • [33] Impact of monthly headache days on migraine-related quality of life: Results from the CaMEO study
    Lipton, R. B.
    Pozo-Rosich, P.
    Orr, S. L.
    Reed, M. L.
    Fanning, K. M.
    Dabruzzo, B. L.
    Buse, D. C.
    HEADACHE, 2022, 62 : 18 - 19
  • [34] Rimegepant 75 mg is Associated With Significant Reductions in Monthly Migraine Days: Post-Hoc Analyses of a Multicenter, Open Label Long-Term Safety Study of Rimegepant for the Acute Treatment of Migraine
    McGinley, J. S.
    L'Italien, G. J.
    Thiry, A. C.
    Croop, R.
    Coric, V
    Lipton, R. B.
    HEADACHE, 2020, 60 : 118 - 120
  • [35] Psychometric Evaluation of the Migraine-Specific Quality of Life Questionnaire (MSQ v2.1) Using Data From Phase 3 Clinical Trials in Patients With Chronic Migraine (CM) and Episodic Migraine (EM)
    Stokes, Jonathan
    Dodick, David
    Lipton, Richard
    Whalley, Diane
    Savva, Yulia
    Gelhorn, Heather
    Nelson, Lauren
    Yarr, Stuart
    Gandhi, Pranav
    NEUROLOGY, 2023, 100 (17)
  • [36] Association and Impact of Monthly Migraine Headache Frequency and Pain Intensity on Comorbidities and Concomitant Health Conditions: Results from the Migraine in America Symptoms and Treatment (MAST) Study
    Buse, D.
    Reed, M. L.
    Bostic, R.
    Munjal, S.
    Bensimon, L.
    Singh, P.
    Lipton, R. B.
    HEADACHE, 2019, 59 : 184 - 186
  • [37] Sustained response to atogepant in individuals with episodic migraine: Post hoc analyses of 12-and 52-week phase 3 trials
    Lipton, R. B.
    Nahas, S. J.
    Pozo-Rosich, P.
    Bilchik, T. R.
    McAllister, P.
    Finnegan, M.
    Ma, J.
    Chalermpalanupap, T.
    Dabruzzo, B. L.
    Dodick, D. W.
    HEADACHE, 2022, 62 : 165 - 166
  • [38] Sustained Response to Atogepant in Individuals with Episodic Migraine: Post Hoc Analyses of 12-and 52-Week Phase 3 Trials
    Lipton, R.
    Nahas, S.
    Pozo-Rosich, P.
    Bilchik, T.
    McAllister, P.
    Finnegan, M.
    Ma, J.
    Chalermpalanupap, T.
    Dabruzzo, B.
    Dodick, D.
    JOURNAL OF HEADACHE AND PAIN, 2022, 23 (SUPPL 1):
  • [39] Impact of Prior Monthly Headache Days on Migraine-Related Quality of Life: Results From the CaMEO Study
    Lipton, R. B.
    Pozo-Rosich, P.
    Orr, S. L.
    Reed, M. L.
    Fanning, K. M.
    Dabruzzo, B.
    Buse, D. C.
    CEPHALALGIA, 2021, 41 (1_SUPPL) : 144 - 144
  • [40] Reading data in migraine acute treatment studies: From clinical trials to reviews and meta-analyses
    Buzzi M.G.
    The Journal of Headache and Pain, 2006, 7 (3) : 160 - 164
12345